
Page#1
Table of Contents
CARDLYTICS, INC.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except par value amounts)
 December 31,
 2018 2019
Assets 
Current assets: 
Cash and cash equivalents $ 39,623 $ 104,458
Restricted cash 20,247 129
Accounts receivable, net 58,125 81,452
Other receivables 2,417 3,908
Prepaid expenses and other assets 3,956 5,783
Total current assets 124,368 195,730
Long-term assets:
Property and equipment, net 10,230 14,290
Intangible assets, net 370 389
Capitalized software development costs, net 1,625 3,815
Deferred FI implementation costs, net 15,877 8,383
Other long-term assets, net 1,293 1,706
Total assets $ 153,763 $ 224,313
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 2,099 $ 1,229
Accrued liabilities:
Accrued compensation 5,936 8,186
Accrued expenses 4,388 6,018
FI Share liability 27,656 41,956
Consumer Incentive liability 11,476 19,861
Deferred revenue 346 1,127
Current portion of long-term debt 21 24
Total current liabilities 51,922 78,401
Long-term liabilities:
Deferred liabilities 3,173 2,632
Long-term debt, net of current portion 46,693 13
Total liabilities 101,788 81,046
Stockholders’ equity:
Common stock, $0.0001 par value—100,000 shares authorized and 22,466 and 26,547 shares issued and outstanding
as of December 31, 2018 and December 31, 2019, respectively 7 8
Additional paid-in capital 371,463 480,578
Accumulated other comprehensive income 1,992 1,312
Accumulated deficit (321,487) (338,631)
Total stockholders’ equity 51,975 143,267
Total liabilities and stockholders’ equity $ 153,763 $ 224,313
See notes to the consolidated financial statements
67
Page#2
Table of Contents
CARDLYTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share amounts)
 Year Ended December 31,
 2017  2018  2019
Revenue $ 130,365  $ 150,684  $ 210,430
Costs and expenses:  
FI Share and other third-party costs 73,247  85,371  118,080
Delivery costs 7,012  10,632  12,893
Sales and marketing expense 31,927  41,878  43,828
Research and development expense 12,150  16,210  11,699
General and administration expense 20,100  34,228  36,720
Depreciation and amortization expense 3,028  3,282  4,535
Total costs and expenses 147,464  191,601  227,755
Operating loss (17,099)  (40,917)  (17,325)
Non-operating (expense) income:  
Interest expense, net (8,239)  (3,264)  (548)
Change in fair value of warrant liabilities, net (581)  (6,760)  —
Change in fair value of convertible promissory notes (1,244)  —  —
Change in fair value of convertible promissory notes—related parties 6,213  —  —
Other income (expense), net 1,309  (2,101)  729
Total non-operating (expense) income (2,542)  (12,125)  181
Loss before income taxes (19,641)  (53,042)  (17,144)
Income tax benefit —  —  —
Net loss (19,641)  (53,042)  (17,144)
Adjustments to the carrying value of redeemable convertible preferred stock (5,743)  (157)  —
Net loss attributable to common stockholders $ (25,384)  $ (53,199)  $ (17,144)
Net loss per share attributable to common stockholders, basic and diluted
$ (7.86)  $ (2.79)  $ (0.72)
Weighted-average common shares outstanding, basic and diluted
3,230  19,060  23,746
See notes to the consolidated financial statements
68
Page#3
Table of Contents
CARDLYTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
 Year Ended December 31,
 2017 2018 2019
Operating activities 
 Net loss $ (19,641)  $ (53,042)  $ (17,144)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: 
Depreciation and amortization 3,028  3,282  4,535
Amortization of financing costs charged to interest expense 560  282  95
Accretion of debt discount and non-cash interest expense 6,889  2,326  —
Stock-based compensation expense 5,147  26,790  15,851
Change in the fair value of warrant liabilities, net 581  6,760  —
Change in the fair value of convertible promissory notes 1,244  —  —
Change in the fair value of convertible promissory notes - related parties (6,213)  —  —
Other non-cash (income) expense, net (1,102)  4,771  631
Amortization of deferred FI implementation costs 1,626  1,618  2,869
Settlement of paid-in-kind interest —  (8,353)  —
Change in operating assets and liabilities: 
Accounts receivable (7,503)  (9,426)  (26,018)
Prepaid expenses and other assets (666)  (2,275)  (2,224)
Deferred FI implementation costs (10,900)  (9,250)  —
Recovery of deferred FI implementation costs 4,100  5,380  4,625
Accounts payable (1,907)  911  (601)
Other accrued expenses 466  3,255  6,152
FI Share liability 804  3,742  14,301
Customer Incentive liability 1,385  4,234  8,385
Net cash (used in) provided by operating activities (22,102)  (18,995)  11,457
Investing activities 
Acquisition of property and equipment (1,215)  (5,920)  (8,277)
Acquisition of patents (60)  (23)  (31)
Capitalized software development costs (372)  (1,399)  (2,712)
Net cash used in investing activities (1,647)  (7,342)  (11,020)
Financing activities 
Proceeds from issuance of debt 12,500  47,435  —
Principal payments of debt (99)  (52,581)  (46,698)
Proceeds from issuance of common stock 230  72,334  91,216
Proceeds from issuance of Series G preferred stock 11,940  —  —
Equity issuance costs (2,668)  (1,949)  (196)
Debt issuance costs (142)  (48)  (143)
Net cash provided by financing activities 21,761  65,191  44,179
Effect of exchange rates on cash, cash equivalents and restricted cash 282  (246)  101
Net (decrease) increase in cash, cash equivalents and restricted cash (1,706)  38,608  44,717
Cash, cash equivalents, and restricted cash — Beginning of period 22,968  21,262  59,870
Cash, cash equivalents, and restricted cash — End of period $ 21,262  $ 59,870  $ 104,587
See notes to the consolidated financial statements
71